Additional file 2: of Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial Jessica Gordon Viktor Martyanov Cynthia Magro Horatio Wildman Tammara Wood Wei-Ti Huang Mary Crow Michael Whitfield Robert Spiera 10.6084/m9.figshare.c.3636080_D5.v1 https://springernature.figshare.com/articles/journal_contribution/Additional_file_2_of_Nilotinib_Tasigna_in_the_treatment_of_early_diffuse_systemic_sclerosis_an_open-label_pilot_clinical_trial/4440452 Dermatopathology results. αSMA alpha smooth muscle actin, Egr early growth response protein. (DOCX 15 kb) 2015-08-18 05:00:00 muscle actin Additional trial Dermatopathology results growth response protein Nilotinib open-label DOCX 15 kb Egr α SMA Tasigna sclerosis